FDA Approves Tucatinib Combination for HER2-Positive Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved tucatinib in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer. This approval follows induction treatment and was evaluated in the HER2CLIMB-05 trial involving 654 adult patients.